Showing results (91-100 of 253) with videos related to
Sort By:
Pageof 26
Journal of the American Society of Nephrology : JASN|April 9, 2016
Determining the Optimal Protocol for Measuring an Albuminuria Class Transition in Clinical Trials in Diabetic Kidney DiseaseTobias F Kröpelin, Dick de Zeeuw, Giuseppe Remuzzi, et al.Diabetologia|October 8, 2018
A cost analysis of intensified vs conventional multifactorial therapy in individuals with type 2 diabetes: a post hoc analysis of the Steno-2 studyJoachim Gæde, Jens Oellgaard, Rikke Ibsen, et al.Scandinavian Journal of Clinical and Laboratory Investigation|January 25, 2012
The effect of RAAS blockade on markers of renal tubular damage in diabetic nephropathy: u-NGAL, u-KIM1 and u-LFABPStine E Nielsen, Kasper Rossing, Georg Hess, et al.Acta Ophthalmologica Scandinavica|March 22, 2002
Cataract surgery on diabetic patients. A prospective evaluation of risk factors and complicationsPer Flesner, Birgit Sander, Vibeke Henning, et al.The Journal of Clinical Endocrinology and Metabolism|January 24, 2008
Plasma alpha-defensin is associated with cardiovascular morbidity and mortality in type 1 diabetic patientsGowsini Joseph, Lise Tarnow, Anne Sofie Astrup, et al.Kidney International|June 12, 2014
Improved prognosis of diabetic nephropathy in type 1 diabetesGudbjörg Andrésdóttir, Majken L Jensen, Bendix Carstensen, et al.Journal of Negative Results in Biomedicine|May 10, 2011
The CTGF -945GC polymorphism is not associated with plasma CTGF and does not predict nephropathy or outcome in type 1 diabetesAmélie Dendooven, Tri Q Nguyen, Lodewijk Brosens, et al.Lancet (London, England)|October 1, 2008
Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trialsNish Chaturvedi, Massimo Porta, Ronald Klein, et al.Lancet (London, England)|October 1, 2008
Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trialAnne Katrin Sjølie, Ronald Klein, Massimo Porta, et al.Journal of Hypertension|October 8, 2009
Antihypertensive effects of double the maximum dose of valsartan in African-American patients with type 2 diabetes mellitus and albuminuriaMatthew R Weir, Norman K Hollenberg, Dion H Zappe, et al.Pageof 26